Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients

Improved therapies are urgently needed for patients with diffuse large B cell lymphoma (DLBCL). Success using immune checkpoint inhibitors and chimeric antigen receptor T cell technology has fuelled demand for validated cancer epitopes. Immunogenic cancer testis antigens (CTAs), with their widesprea...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Adv Hematol
Main Authors: Ait-Tahar, Kamel, Anderson, Amanda P., Barnardo, Martin, Collins, Graham P., Hatton, Chris S. R., Banham, Alison H., Pulford, Karen
Formato: Artigo
Idioma:Inglês
Publicado: Hindawi 2017
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5674480/
https://ncbi.nlm.nih.gov/pubmed/29204156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/6527306
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares